No results were found for your search. Please adjust your search term or broaden your search criteria.
Still can't find what you are looking for? We can prepare Custom Research for you.
Venclexta (venetoclax) is a drug used to treat certain types of chronic lymphocytic leukemia (CLL). It is a BCL-2 inhibitor, meaning it works by blocking the action of a protein called BCL-2, which helps cancer cells survive. Venclexta is approved for use in combination with other drugs, such as rituximab, to treat CLL in adults who have received at least one prior therapy. It is also approved for use as a single agent to treat CLL in adults with a certain genetic mutation.
The Venclexta market is a rapidly growing segment of the global oncology market. It is estimated that the market will reach $2.5 billion by 2026, driven by the increasing prevalence of CLL and the growing demand for targeted therapies. The market is highly competitive, with several major players offering Venclexta-based treatments.
Some of the companies in the Venclexta market include AbbVie, Genentech, and Gilead Sciences. AbbVie markets Venclexta in combination with rituximab under the brand name Venclyxto. Genentech markets Venclexta as a single agent under the brand name Venclexta. Gilead Sciences markets Venclexta in combination with obinutuzumab under the brand name Venclexta Plus. Show Less Read more
